Article
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Cells - 24 Mar 2021
Saafan Hisham, Alahdab Ahmad, Michelet Robin, Gohlke Linus, Ziemann Janine, Holdenrieder Stefan, McLaughlin Katie-May, Wass Mark N, Cinatl Jindrich, Michaelis Martin, Kloft Charlotte, Ritter Christoph A
Abstract excerpt
Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.